Fawad Virk, MD
Interventional Cardiology · Rolla, MONPI 1396150165
Payments from drug & device makers
Across 261 payments — averaging $46.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Medtronic$2K
- Abiomed$1K
- Philips North America LLC$1K
- Biotronik Inc.$695
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$684
- plus $4K from 24 others
What the payments were for
- Grants$1,1059%
- Travel & lodging$2,68622%
- Food & beverage$7,80765%
- Education$3873%
- Gifts$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 25 | $2,458 |
| Medtronic(2 entities) | 24 | $1,855 |
| Abiomed | 15 | $1,221 |
| Philips North America LLC | 9 | $1,076 |
| Biotronik Inc. | 3 | $695 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 48 | $684 |
| Abbott | 16 | $638 |
| Novartis | 36 | $587 |
| Amgen | 21 | $545 |
| Inari Medical, Inc. | 2 | $372 |
| Boehringer Ingelheim | 13 | $291 |
| Johnson & Johnson | 6 | $263 |
| Edwards Lifesciences | 2 | $222 |
| AstraZeneca | 8 | $207 |
| E.r. Squibb & Sons, L.L.C. | 7 | $203 |
| Nuwellis, Inc. | 1 | $101 |
| Pfizer | 2 | $99 |
| Shockwave Medical, Inc | 2 | $97 |
| Angiodynamics, Inc. | 3 | $80 |
| Chiesi USA, Inc. | 1 | $75 |
| Novo Nordisk | 4 | $66 |
| Bayer | 2 | $39 |
| Cvrx, Inc. | 2 | $33 |
| Actelion Pharmaceuticals US, Inc. | 1 | $32 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Lexicon Pharmaceuticals, Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 2 | $24 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Terumo Medical Corporation | 1 | $14 |
| Teleflex LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,342
- GENERAL - STRUCTURAL HEART$1,105
- (9520) IGT Devices Undivided$571
- FLOWTRIEVER CATHETER, S$372
- CT THROMBECTOMY SYSTEM KIT$372
- Impella$245
- Repatha$234
- Ensite Cardiac Mapping System$212
- GENERAL VASCULAR INTERVENTION$150
- Resolute$140
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$140
- Watchman$119
- (6571) Eagle Eye$114
- (6575) Coronary Undivided$113
- XARELTO$107
- ELIQUIS$104
- GENERAL - THERAPIES$102
- Aquadex$101
How this compares
$12,060 in reported general payments places this provider in the 45th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 283 | $265,546 |
| JardianceEmpagliflozin | 186 | $190,043 |
| EntrestoSacubitril/Valsartan | 124 | $136,918 |
| BrilintaTicagrelor | 28 | $21,551 |
| XareltoRivaroxaban | 23 | $20,170 |
| FarxigaDapagliflozin Propanediol | 16 | $12,401 |
| VascepaIcosapent Ethyl | 11 | $7,764 |
| DapagliflozinDapagliflozin Propanediol | 12 | $5,838 |
| Metoprolol Succinate | 505 | $5,661 |
| Ranolazine ErRanolazine | 39 | $2,400 |
| Atorvastatin Calcium | 254 | $2,349 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 90 | $2,309 |
| Potassium Chloride | 120 | $1,978 |
| Ezetimibe | 114 | $1,968 |
| Rosuvastatin Calcium | 189 | $1,774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $99 | $265,546283 claims |
| Boehringer IngelheimJardiance | $291 | $190,043186 claims |
| NovartisEntresto | $587 | $136,918124 claims |
| AstraZenecaBrilinta, Farxiga | $207 | $33,95244 claims |
| Johnson & JohnsonXarelto | $263 | $20,17023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Rolla
- Stilianos EfstratiadisRolla$49K
- Harvey SerotaSaint Louis$7.1M
- Adnan ChhatriwallaKansas City$3.6M
- Gil VardiSaint Louis$2M
- Alan ZajariasSaint Louis$1.6M
- James GranthamKansas City$1.6M
- Anish ThomasSaint Louis$1.5M
- Richard BachSaint Louis$1.5M
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$995K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.